Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 49 points (0.3%) at 16,411 as of Monday, April 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,415 issues advancing vs. 1,576 declining with 152 unchanged. The Health Services industry currently sits down 1.3% versus the S&P 500, which is unchanged. A company within the industry that increased today was Smith & Nephew ( SNN), up 0.8%. On the negative front, top decliners within the industry include Haemonetics ( HAE), down 8.7%, Icon ( ICLR), down 7.0%, Parexel International ( PRXL), down 6.4%, Charles River Laboratories International In ( CRL), down 5.2% and Covance ( CVD), down 3.3%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. CareFusion ( CFN) is one of the companies pushing the Health Services industry higher today. As of noon trading, CareFusion is up $0.26 (0.7%) to $38.42 on heavy volume. Thus far, 1.2 million shares of CareFusion exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $38.19-$38.72 after having opened the day at $38.30 as compared to the previous trading day's close of $38.16. CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. CareFusion has a market cap of $8.0 billion and is part of the health care sector. The company has a P/E ratio of 24.5, above the S&P 500 P/E ratio of 17.7. Shares are down 4.2% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.